Información del artículo
Abstract
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological complication of cancer treatment, affecting a third of all patients who undergo chemotherapy. CIPN impairs functional capacity, compromises the quality of life and results in dose reduction or cessation of chemotherapy, representing a dose-limiting side effect of many antineoplastic drugs. In addition to classic, novel agents, bortezomib and oxaliplatin have been shown to have a significant risk of CIPN.
MethodsBy reviewing literature, this article analyses relevant issues and recent advances regarding the pathogenesis, incidence, risk factors, diagnosis, characteristics and management of CIPN.
ResultsResearch into the pathophysiology and identification of risk factors for individual patients is growing. A future avenue of investigation includes the identification of patients at lower or higher risk based on their genotype. Best tools for CIPN assessment are not defined. Many agents have been claimed to be neuroprotectors without showing significant results in large randomised clinical trials.
ConclusionsEarly recognition and subsequent dose reduction/discontinuation of the offending agent is the only way to minimise the development of this potentially debilitating complication. Due to the lack of effective prophylactic or symptomatic treatments up to now, neurological monitoring should be recommended in patient candidates to be treated with neurotoxic antineoplastic agents, mainly when they present baseline neuropathy. Development of reliable methods for CIPN assessment is essential.
Keywords:
Chemotherapy-induced peripheral neuropathy
Chemotherapy
Neuropathy
Toxic neuropathy
Antineoplastic agent
Resumen
Introducción
La neuropatía periférica inducida por quimioterapia (NIQ) es la complicación neurológica más frecuente del tratamiento del cáncer, y afecta aproximadamente a una tercera parte de los pacientes. La NIQ deteriora la funcionalidad, compromete la calidad de vida y, frecuentemente, conlleva la reducción y/o suspensión del tratamiento, lo que representa un efecto adverso limitante de dosis de muchos antineoplásicos. Además de los clásicos, agentes nuevos como bortezomib y oxaliplatino presentan un marcado riesgo de neuropatía.
MétodosTras revisión de la literatura, se analizan los trabajos relevantes y los recientes avances sobre patogenia, incidencia, factores de riesgo, diagnóstico, características y manejo de la NIQ.
ResultadosEl conocimiento sobre la fisiopatología de la NIQ es creciente. La investigación incluye la identificación de los genes relacionados con un mayor o menor riesgo de NIQ. La mejor herramienta que permita diagnosticar y graduar la severidad de la NIQ no está definida. Numerosos agentes se están investigando como potenciales neuroprotectores o tratamientos sintomáticos, con resultados negativos en la mayoría de ellos.
ConclusionesEl reconocimiento precoz y posterior reducción de dosis o suspensión del agente neurotóxico es actualmente la única forma de minimizar el desarrollo de esta complicación. Ante la ausencia de tratamientos preventivos o sintomáticos eficaces en la NIQ, sería recomendable la monitorización neurológica de los pacientes candidatos a recibir quimioterapia con agentes neurotóxicos, sobre todo si presentan una neuropatía de base o subclínica. Es necesario definir e implementar la mejor medida para evaluar la NIQ.
Palabras clave:
Neuropatía inducida por quimioterapia
Quimioterapia
Neuropatía
Neuropatía tóxica
Agente antineoplásico
El Texto completo está disponible en PDF
References
[1.]
G. Kannarkat, E.E. Lasher, D. Schiff.
Neurologic complications of chemotherapy agents.
Curr Opin Neurol, 20 (2007), pp. 719-725
[2.]
A. Kedar, M.E. Cohen, A.I. Freeman.
Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: a case report.
Cancer Treat Rep, 62 (1978), pp. 819-821
[3.]
A.A. Argyriou, G. Iconomou, H.P. Kalofonos.
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Blood, 112 (2008), pp. 1593-1599
[4.]
A.A. Argyriou, M. Koltzenburg, P. Polychronopoulos, S. Papapetropoulos, H.P. Kalofonos.
Peripheral nerve damage associated with administration of taxanes in patients with cancer.
Crit Rev Oncol Hematol, 66 (2008), pp. 218-228
[5.]
A.A. Argyriou, P. Polychronopoulos, G. Iconomou, E. Chroni, H.P. Kalofonos.
A review on oxaliplatin-induced peripheral nerve damage.
Cancer Treat Rev, 34 (2008), pp. 368-377
[6.]
B. Malik, M. Stillman.
Chemotherapy-induced peripheral neuropathy.
Curr Pain Headache Rep, 12 (2008), pp. 165-174
[7.]
S.M. Swain, J.C. Arezzo.
Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
Clin Adv Hematol Oncol, 6 (2008), pp. 455-467
[8.]
L.H. Weimer, N. Sachdev.
Update on medication-induced peripheral neuropathy.
Curr Neurol Neurosci Rep, 9 (2009), pp. 69-75
[9.]
A.J. Windebank, W. Grisold.
Chemotherapy-induced neuropathy.
J Peripher Nerv Syst, 13 (2008), pp. 27-46
[10.]
C. Iñiguez, P. Larrodé, J.I. Mayordomo, J.A. Mauri, A. Trés, F. Morales.
Peripheral nervous system neurotoxicity secondary to chemotherapy treatment.
Neurologia, 15 (2000), pp. 343-351
[11.]
J.P. Cata, H.R. Weng, B.N. Lee, J.M. Reuben, P.M. Dougherty.
Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy.
Minerva Anestesiol, 72 (2006), pp. 151-169
[12.]
G. Cavaletti, L. Marzorati, G. Bogliun, N. Colombo, M. Marzola, M.R. Pittelli, et al.
Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.
Cancer, 69 (1992), pp. 203-207
[13.]
S. Mielke, K. Mross, T.A. Gerds, A. Schmidt, R. Wäsch, D.P. Berger, et al.
Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3h.
Anticancer Drugs, 14 (2003), pp. 785-792
[14.]
A.D. Seidman, C.A. Hudis, J. Albanell, W. Tong, I. Tepler, V. Currie, et al.
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
J Clin Oncol, 16 (1998), pp. 3353-3361
[15.]
L. Mileshkin, H.M. Prince.
The troublesome toxicity of peripheral neuropathy with thalidomide.
Leuk Lymphoma, 47 (2006), pp. 2276-2279
[16.]
T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, et al.
National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
N Engl J Med, 352 (2005), pp. 2589-2597
[17.]
T.J. Postma, J.J. Heimans.
Grading of chemotherapy-induced peripheral neuropathy.
Ann Oncol, 11 (2000), pp. 509-513
[18.]
A. Pace, L. Bove, C. Nisticò, M. Ranuzzi, P. Innocenti, A. Pietrangeli, et al.
Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients.
J Neurol Neurosurg Psychiatry, 61 (1996), pp. 409-411
[19.]
J.J. Lee, J.A. Low, E. Croarkin, R. Parks, A.W. Berman, N. Mannan, et al.
Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.
J Clin Oncol, 24 (2006), pp. 2084-2091
[20.]
M. Markman.
Chemotherapy-associated neurotoxicity: an important side-effect- impacting on quality-rather than quantity, of life.
J Cancer Res Clin Oncol, 122 (1996), pp. 511-512
[21.]
K. Shimozuma, Y. Ohashi, A. Takeuchi, T. Aranishi, S. Morita, K. Kuroi, et al.
Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.
Support Care Cancer, 17 (2009), pp. 1483-1491
[22.]
R. Wickham.
Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.
Clin J Oncol Nurs, 11 (2007), pp. 361-376
[23.]
L. Vahdat, K. Papadopoulos, D. Lange, S. Leuin, E. Kaufman, D. Donovan, et al.
Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Clin Cancer Res, 7 (2001), pp. 1192-1197
[24.]
A.A. Argyriou, P. Polychronopoulos, A. Koutras, G. Iconomou, A. Iconomou, H.P. Kalofonos, et al.
Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?.
Support Care Cancer, 13 (2005), pp. 647-651
[25.]
A.A. Argyriou, P. Polychronopoulos, G. Iconomou, A. Koutras, T. Makatsoris, M.K. Gerolymos, et al.
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Acta Oncol, 46 (2007), pp. 1131-1137
[26.]
F. Lanzani, L. Mattavelli, B. Frigeni, F. Rossini, S. Cammarota, D. Petrò, et al.
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
J Peripher Nerv Syst, 13 (2008), pp. 267-274
[27.]
Z. Nurgalieva, R. Xia, C.C. Liu, K. Burau, D. Hardy, X.L. Du.
Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer.
Am J Ther, 17 (2010), pp. 148-158
[28.]
S. Wolf, D. Barton, L. Kottschade, A. Grothey, C. Loprinzi.
Chemotherapy-induced peripheral neuropathy: prevention treatment strategies.
Eur J Cancer, 44 (2008), pp. 1507-1515
[29.]
A. Bhagra, R.D. Rao.
Chemotherapy-induced neuropathy.
Curr Oncol Rep, 9 (2007), pp. 290-299
[30.]
G. Cavaletti, P. Marmiroli.
The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity.
Curr Drug Saf, 1 (2006), pp. 35-42
[31.]
V. Chaudhry, E.K. Rowinsky, S.E. Sartorius, R.C. Donehower, D.R. Cornblath.
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Ann Neurol, 35 (1994), pp. 304-311
[32.]
M. Von Schlippe, C.J. Fowler, S.J. Harland.
Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis.
Br J Cancer, 85 (2001), pp. 823-826
[33.]
J.A. Sparano, M. Wang, S. Martino, V. Jones, E.A. Perez, T. Saphner, et al.
Weekly paclitaxel in the adjuvant treatment of breast cancer.
N Engl J Med, 358 (2008), pp. 1663-1671
[34.]
G. Cavaletti, G. Bogliun, L. Marzorati, A. Zincone, M. Marzola, N. Colombo, et al.
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.
Cancer, 75 (1995), pp. 1141-1150
[35.]
S. Mielke, A. Sparreboom, K. Mross.
Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.
Eur J Cancer, 42 (2006), pp. 24-30
[36.]
D. Loven, H. Levavi, G. Sabach, R. Zart, M. Andras, A. Fishman, et al.
Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
Eur J Cancer Care (Engl), 18 (2009), pp. 78-83
[37.]
S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, et al.
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
J Clin Oncol, 23 (2005), pp. 5542-5551
[38.]
L.C. Pronk, P.H. Hilkens, M.J. Van den Bent, W.L. Van Putten, G. Stoter, J. Verweij.
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Anticancer Drugs, 9 (1998), pp. 759-764
[39.]
A.H. Sarris, F. Hagemeister, J. Romaguera, M.A. Rodriguez, P. McLaughlin, A.M. Tsimberidou, et al.
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
Ann Oncol, 11 (2000), pp. 69-72
[40.]
H. Kelly, R.M. Goldberg.
Systemic therapy for metastatic colorectal cancer: current options, current evidence.
J Clin Oncol, 23 (2005), pp. 4553-4560
[41.]
A. Grothey.
Clinical management of oxaliplatin-associated neurotoxicity.
Clin Colorectal Cancer, 5 (2005), pp. S38-S46
[42.]
A. De Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, et al.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
J Clin Oncol, 18 (2000), pp. 2938-2947
[43.]
J.F. San Miguel, R. Schlag, N.K. Khuageva, M.A. Dimopoulos, O. Shpilberg, M. Kropff, et al.
VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med, 359 (2008), pp. 906-917
[44.]
J.T. Hartmann, H.P. Lipp.
Toxicity of platinum compounds.
Expert Opin Pharmacother, 4 (2003), pp. 889-901
[45.]
G.P. Kim, C. Erlichman.
Oxaliplatin in the treatment of colorectal cancer.
Expert Opin Drug Metab Toxicol, 3 (2007), pp. 281-294
[46.]
A.A. Argyriou, P. Polychronopoulos, G. Iconomou, A. Koutras, T. Makatsoris, M.K. Gerolymos, et al.
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Acta Oncol, 46 (2007), pp. 1131-1137
[47.]
T. André, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, et al.
Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
N Engl J Med, 350 (2004), pp. 2343-2351
[48.]
P.G. Richardson, W. Xie, C. Mitsiades, A.A. Chanan-Khan, S. Lonial, H. Hassoun, et al.
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
J Clin Oncol, 27 (2009), pp. 3518-3525
[49.]
P.G. Richardson, H. Briemberg, S. Jagannath, P.Y. Wen, B. Barlogie, J. Berenson, et al.
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
J Clin Oncol, 24 (2006), pp. 3113-3120
[50.]
M. Offidani, L. Corvatta, M. Marconi, L. Malerba, A. Mele, A. Olivieri, et al.
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
Eur J Haematol, 72 (2004), pp. 403-409
[51.]
S.V. Rajkumar.
Thalidomide in the treatment of multiple myeloma.
Expert Rev Anticancer Ther, 1 (2001), pp. 20-28
[52.]
R. Plasmati, F. Pastorelli, M. Cavo, E. Petracci, E. Zamagni, P. Tosi, et al.
Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Neurology, 69 (2007), pp. 573-581
[53.]
L. Mileshkin, R. Stark, B. Day, J.F. Seymour, J.B. Zeldis, H.M. Prince.
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
J Clin Oncol, 24 (2006), pp. 4507-4514
[54.]
B. Kocer, G. Sucak, R. Kuruoglu, Z. Aki, R. Haznedar, N.I. Erdogmus.
Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
Acta Neurol Belg, 109 (2009), pp. 120-126
[55.]
S. Goel, G.L. Goldberg, D.Y. Kuo, F. Muggia, J. Arezzo, S. Mani.
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.
Ann Oncol, 19 (2008), pp. 2048-2052
[56.]
Emea. Available from:http://www.emea.europa.eu/humandocs/PDFs/EPAR/ixempra/H-930-Q&A es.pdf.
[57.]
G. Cavaletti.
Chemotherapy-induced peripheral neurotoxicity: how can we improve knowledge?.
Lancet Oncol, 10 (2009), pp. 539-540
[58.]
M.R. Litzow.
Arsenic trioxide.
Expert Opin Pharmacother, 9 (2008), pp. 1773-1785
[59.]
Lenalidomide: new drug.
Myeloma: many questions remain unanswered.
Prescrire Int, 17 (2008), pp. 230-232
[60.]
A. Badros, O. Goloubeva, J.S. Dalal, I. Can, J. Thompson, A.P. Rapoport, et al.
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Cancer, 110 (2007), pp. 1042-1049
[61.]
P.S. Spencer.
Biological principles of chemical neurotoxicity.
Experimental and Clinical Neurotoxicology, 2nd ed, pp. 3-54
[62.]
J.S. Gill, A.J. Windebank.
Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.
J Clin Invest, 101 (1998), pp. 2842-2850
[63.]
A. Scuteri, A. Galimberti, D. Maggioni, M. Ravasi, S. Pasini, G. Nicolini, et al.
Role of MAPKs in platinum-induced neuronal apoptosis.
Neurotoxicology, 30 (2009), pp. 312-319
[64.]
E.K. Rowinsky, R.C. Donehower.
The clinical pharmacology of paclitaxel (Taxol).
Semin Oncol, 20 (1993), pp. 16-25
[65.]
M.S. Wang, A.A. Davis, D.G. Culver, Q. Wang, J.C. Powers, J.D. Glass.
Calpain inhibition protects against Taxol-induced sensory neuropathy.
Brain, 127 (2004), pp. 671-679
[66.]
M.S. Wang, Y. Wu, D.G. Culver, J.D. Glass.
Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy.
J Neuropathol Exp Neurol, 59 (2000), pp. 599-606
[67.]
L. Aloe, L. Manni, F. Properzi, S. De Santis, M. Fiore.
Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis.
Auton Neurosci, 86 (2000), pp. 84-93
[68.]
S. De Santis, A. Pace, L. Bove, F. Cognetti, F. Properzi, M. Fiore, et al.
Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor.
Clin Cancer Res, 6 (2000), pp. 90-95
[69.]
G. Cavaletti, G. Pezzoni, C. Pisano, N. Oggioni, F. Sala, C. Zoia, et al.
Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor.
Neurosci Lett, 322 (2002), pp. 103-106
[70.]
G. Cavaletti, G. Bogliun, L. Marzorati, A. Zincone, M. Piatti, N. Colombo, et al.
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.
Ann Oncol, 15 (2004), pp. 1439-1442
[71.]
R. Kirchmair, D.H. Walter, M. Li, K. Rittig, A.B. Tietz, T. Murayama, et al.
Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.
Circulation, 111 (2005), pp. 2662-2670
[72.]
B.J. Giantonio, P.J. Catalano, N.J. Meropol, P.J. O’Dwyer, E.P. Mitchell, S.R. Alberts, et al.
Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
J Clin Oncol, 25 (2007), pp. 1539-1544
[73.]
N.I. Weijl, F.J. Cleton, S. Osanto.
Free radicals and antioxidants in chemotherapy-induced toxicity.
Cancer Treat Rev, 23 (1997), pp. 209-240
[74.]
F. Grolleau, L. Gamelin, M. Boisdron-Celle, B. Lapied, M. Pelhate, E. Gamelin.
A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.
J Neurophysiol, 85 (2001), pp. 2293-2297
[75.]
S.B. Park, C.S. Lin, A.V. Krishnan, D. Goldstein, M.L. Friedlander, M.C. Kiernan.
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Brain, 132 (2009), pp. 2712-2723
[76.]
J. Bruna, E. Udina, A. Alé, J. Monbaliu, E. Verdú, A. Vynckier, et al.
Neurophysiological and histological characterization of bortezomib-induced neuropathy in mice.
J Peripher Nerv Syst, 14 (2009), pp. 22
[77.]
G. Cavaletti, A. Gilardini, A. Canta, L. Rigamonti, V. Rodriguez-Menendez, C. Ceresa, et al.
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.
Exp Neurol, 204 (2007), pp. 317-325
[78.]
I. Casafont, M.T. Berciano, M. Lafarga.
Bortezomib induced the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.
Neurotox Res, 17 (2010), pp. 167-178
[79.]
C. Meregalli, A. Canta, V.A. Carozzi, A. Chiorazzi, N. Oggioni, A. Gilardini, et al.
Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats.
Eur J Pain, (2009),
[80.]
T.J. Kaley, L.M. Deangelis.
Therapy of chemotherapy-induced peripheral neuropathy.
Br J Haematol, 145 (2009), pp. 3-14
[81.]
J. Choi, K. Kong, T. Mozaffar, R.F. Holcombe.
Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.
Anticancer Drugs, 17 (2006), pp. 103-105
[82.]
T. Siegal, N. Haim.
Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps.
Cancer, 66 (1990), pp. 1117-1123
[83.]
S. Quasthoff, H.P. Hartung.
Chemotherapy-induced peripheral neuropathy.
J Neurol, 249 (2002), pp. 9-17
[84.]
C.C. Verstappen, S. Koeppen, J.J. Heimans, P.C. Huijgens, M.E. Scheulen, D. Strumberg, et al.
Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.
Neurology, 64 (2005), pp. 1076-1077
[85.]
P.H. Hilkens, J. Verweij, C.J. Vecht, G. Stoter, M.J. Van den Bent.
Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).
Ann Oncol, 8 (1997), pp. 187-190
[86.]
J.M. Gornet, E. Savier, F. Lokiec, E. Cvitkovic, J.L. Misset, F. Goldwasser.
Exacerbation of oxaliplatin neurosensory toxicity following surgery.
Ann Oncol, 13 (2002), pp. 1315-1318
[87.]
K. Kuroi, K. Shimozuma.
Neurotoxicity of taxanes: symptoms and quality of life assessment.
Breast Cancer, 11 (2004), pp. 92-99
[88.]
S. Taieb, V. Trillet-Lenoir, L. Rambaud, L. Descos, G. Freyer.
Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
Cancer, 94 (2002), pp. 2434-2440
[89.]
B. Dunlap, J.A. Paice.
Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement.
J Support Oncol, 4 (2006), pp. 398-399
[90.]
T.J. Postma, B.A. Benard, P.C. Huijgens, G.J. Ossenkoppele, J.J. Heimans.
Long-term effects of vincristine on the peripheral nervous system.
J Neurooncol, 15 (1993), pp. 23-27
[91.]
G. Zara, M. Ermani, R. Rondinone, S. Arienti, A. Doria.
Thalidomide and sensory neurotoxicity: a neurophysiological study.
J Neurol Neurosurg Psychiatry, 79 (2008), pp. 1258-1261
[92.]
R. Plasmati, F. Pastorelli, M. Cavo, E. Petracci, E. Zamagni, P. Tosi, et al.
Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Neurology, 69 (2007), pp. 573-581
[93.]
A. Krarup-Hansen, S. Helweg-Larsen, H. Schmalbruch, M. Rørth, C. Krarup.
Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.
Brain, 130 (2007), pp. 1076-1088
[94.]
E.M. Ekholm, E.K. Salminen, H.V. Huikuri, J. Jalonen, K.J. Antila, T.A. Salmi, et al.
Impairment of heart rate variability during paclitaxel therapy.
Cancer, 88 (2000), pp. 2149-2153
[95.]
J. San Miguel, J. Bladé, M. Boccadoro, J. Cavenagh, A. Glasmacher, S. Jagannath, et al.
A practical update on the use of bortezomib in the management of multiple myeloma.
Oncologist, 11 (2006), pp. 51-61
[96.]
E. Verdú, J.J. Vilches, F.J. Rodríguez, D. Ceballos, A. Valero, X. Navarro.
Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice.
Muscle Nerve, 22 (1999), pp. 329-340
[97.]
V. Chaudhry, M. Chaudhry, T.O. Crawford, E. Simmons-O’Brien, J.W. Griffin.
Toxic neuropathy in patients with pre-existing neuropathy.
Neurology, 60 (2003), pp. 337-340
[98.]
J. Hildebrand.
Neurological complications of cancer chemotherapy.
Curr Opin Oncol, 18 (2006), pp. 321-324
[99.]
S.A. McGuire, S.M. Gospe Jr., G. Dahl.
Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I.
Med Pediatr Oncol, 17 (1989), pp. 520-523
[100.]
A.M. Orejana-García, J. Pascual-Huerta, A. Pérez-Melero.
Charcot-Marie-Tooth disease and vincristine.
J Am Podiatr Med Assoc, 93 (2003), pp. 229-233
[101.]
R. Yerushalmi, I. Levi, M. Wygoda, G. Ifergane, I. Wirguin.
Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease?.
J Peripher Nerv Syst, 12 (2007), pp. 139-141
[102.]
M.A. Martino, E. Miller, E.C. Grendys Jr..
The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer.
Gynecol Oncol, 97 (2005), pp. 710-712
[103.]
N. Kalfakis, M. Panas, G. Karadima, P. Floroskufi, N. Kokolakis, D. Vassilopoulos.
Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment.
Neurology, 59 (2002), pp. 1470-1471
[104.]
A.C. Peltier, J.W. Russell.
Recent advances in drug-induced neuropathies.
Curr Opin Neurol, 15 (2002), pp. 633-638
[105.]
A.A. Argyriou, P. Polychronopoulos, A. Koutras, G. Iconomou, P. Gourzis, K. Assimakopoulos, et al.
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?.
Support Care Cancer, 14 (2006), pp. 223-229
[106.]
A. Corso, S. Mangiacavalli, M. Varettoni, C. Pascutto, P. Zappasodi, M. Lazzarino.
Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients.
Leuk Res, 34 (2010), pp. 471-474
[107.]
M.V. Mateos, J.M. Hernández, M.T. Hernández, N.C. Gutiérrez, L. Palomera, M. Fuertes, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Blood, 108 (2006), pp. 2165-2172
[108.]
S. Mielke.
Individualized pharmacotherapy with paclitaxel.
Curr Opin Oncol, 19 (2007), pp. 586-589
[109.]
S.R. McWhinney, R.M. Goldberg, H.L. McLeod.
Platinum neurotoxicity pharmacogenetics.
Mol Cancer Ther, 8 (2009), pp. 10-16
[110.]
A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, et al.
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
J Clin Oncol, 25 (2007), pp. 1247-1254
[111.]
T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, M.A. Loriot.
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.
Clin Cancer Res, 12 (2006), pp. 3050-3056
[112.]
A.V. Khrunin, A. Moisseev, V. Gorbunova, S. Limborska.
Genetic polymorphisms the efficacy toxicity of cisplatin-based chemotherapy in ovarian cancer patients.
Pharmacogenomics J, (2009),
[113.]
O. Mir, J. Alexandre, A. Tran, J.P. Durand, G. Pons, J.M. Treluyer, et al.
Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity.
Ann Oncol, 20 (2009), pp. 736-740
[114.]
T.M. Sissung, K. Mross, S.M. Steinberg, D. Behringer, W.D. Figg, A. Sparreboom, et al.
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Eur J Cancer, 42 (2006), pp. 2893-2896
[115.]
T.M. Sissung, C.E. Baum, J. Deeken, D.K. Price, J. Aragon-Ching, S.M. Steinberg, et al.
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Clin Cancer Res, 14 (2008), pp. 4543-4549
[116.]
T.J. Postma, J.J. Heimans, M.J. Muller, G.J. Ossenkoppele, J.B. Vermorken, N.K. Aaronson.
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.
Ann Oncol, 9 (1998), pp. 739-744
[117.]
S. Cascinu, V. Catalano, L. Cordella, R. Labianca, P. Giordani, A.M. Baldelli, et al.
Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
J Clin Oncol, 20 (2002), pp. 3478-3483
[118.]
A.A. Argyriou, P. Polychronopoulos, E. Chroni.
The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy.
Oncologist, 12 (2007), pp. 1371-1372
[119.]
A.A. Argyriou, A. Koutras, P. Polychronopoulos, S. Papapetropoulos, G. Iconomou, G. Katsoulas, et al.
The impact of paclitaxel or cisplatin-based chemotherapy on sympathetic skin response: a prospective study.
J Neurol, 12 (2005), pp. 858-861
[120.]
V. Chaudhry, D.R. Cornblath, M. Polydefkis, A. Ferguson, I. Borrello.
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
J Peripher Nerv Syst, 13 (2008), pp. 275-282
[121.]
D.R. Cornblath, V. Chaudhry, K. Carter, D. Lee, M. Seysedadr, M. Miernicki, et al.
Total neuropathy score: validation and reliability study.
Neurology, 53 (1999), pp. 1660-1664
[122.]
G. Cavaletti, G. Bogliun, L. Marzorati, A. Zincone, M. Piatti, N. Colombo, et al.
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.
Neurology, 61 (2003), pp. 1297-1300
[123.]
Study CI-PERINOMS.Group.
CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study.
J Peripher Nerv Syst, 14 (2009), pp. 69-71
[124.]
M.A. Bakitas.
Background noise: the experience of chemotherapy-induced peripheral neuropathy.
Nurs Res, 56 (2007), pp. 323-331
[125.]
E.A. Calhoun, E.E. Welshman, C.H. Chang, J.R. Lurain, D.A. Fishman, T.L. Hunt, et al.
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.
Int J Gynecol Cancer, 13 (2003), pp. 741-748
[126.]
T.J. Postma, N.K. Aaronson, J.J. Heimans, M.J. Muller, J.G. Hildebrand, J.Y. Delattre, EORTC Quality of Life Group, et al.
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
Eur J Cancer, 41 (2005), pp. 1135-1139
[127.]
S. Pignata, S. De Placido, R. Biamonte, G. Scambia, G. Di Vagno, G. Colucci, et al.
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
BMC Cancer, 6 (2006), pp. 5
[128.]
A.V. Krishnan, D. Goldstein, M. Friedlander, M.C. Kiernan.
Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Muscle Nerve, 32 (2005), pp. 51-60
[129.]
R.G. Van der Hoop, M.E. Van der Burg, W.W. Ten Bokkel Huinink, C. Van Houwelingen, J.P. Neijt.
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
Cancer, 66 (1990), pp. 1697-1702
[130.]
P.G. Richardson, P. Sonneveld, M.W. Schuster, E.A. Stadtmauer, T. Facon, J.L. Harousseau, et al.
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Br J Haematol, 144 (2009), pp. 895-903
[131.]
G. Cavaletti, C. Zanna.
Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity.
Eur J Cancer, 38 (2002), pp. 1832-1837
[132.]
L. Gamelin, M. Boisdron-Celle, R. Delva, V. Guérin-Meyer, N. Ifrah, A. Morel, et al.
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
Clin Cancer Res, 10 (2004), pp. 4055-4061
[133.]
H.S. Hochster, A. Grothey, B.H. Childs.
Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.
J Clin Oncol, 25 (2007), pp. 4028-4029
[134.]
S.C. Apfel, J.C. Arezzo, L. Lipson, J.A. Kessler.
Nerve growth factor prevents experimental cisplatin neuropathy.
Ann Neurol, 31 (1992), pp. 76-80
[135.]
S.C. Apfel, S. Schwartz, B.T. Adornato, R. Freeman, V. Biton, M. Rendell, et al.
Efficacy safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: Arandomized controlled trial. Clinical Investigator rhNGF Group.
JAMA, 284 (2000), pp. 2215-2221
[136.]
B.J. Gwag, F.M. Sessler, V. Robine, J.E. Springer.
Endogenous glutamate levels regulate nerve growth factor mRNA expression in the rat dentate gyrus.
Mol Cells, 7 (1997), pp. 425-430
[137.]
M.D. Stubblefield, L.T. Vahdat, C.M. Balmaceda, A.B. Troxel, C.S. Hesdorffer, C.L. Gooch.
Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.
Clin Oncol (R Coll Radiol), 17 (2005), pp. 271-276
[138.]
W.S. Wang, J.K. Lin, T.C. Lin, W.S. Chen, J.K. Jiang, H.S. Wang, et al.
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Oncologist, 12 (2007), pp. 312-319
[139.]
S. Amara.
Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Ann Pharmacother, 42 (2008), pp. 1481-1485
[140.]
C. Pisano, G. Pratesi, D. Laccabue, F. Zunino, P. Lo Giudice, A. Bellucci, et al.
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.
Clin Cancer Res, 9 (2003), pp. 5756-5767
[141.]
O. Ghirardi, P. Lo Giudice, C. Pisano, M. Vertechy, A. Bellucci, L. Vesci, et al.
Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties.
Anticancer Res, 25 (2005), pp. 2681-2687
[142.]
D.B. Engle, J.A. Belisle, J.A. Gubbels, S.E. Petrie, P.R. Hutson, D.M. Kushner, et al.
Effect of acetyl-l-carnitine on ovarian cancer cells’ proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
Gynecol Oncol, 112 (2009), pp. 631-636
[143.]
G. Bianchi, G. Vitali, A. Caraceni, S. Ravaglia, G. Capri, S. Cundari, et al.
Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine.
Eur J Cancer, 41 (2005), pp. 1746-1750
[144.]
A. Maestri, A. De Pasquale Ceratti, S. Cundari, C. Zanna, E. Cortesi, L. Crinò.
A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy.
Tumori, 91 (2005), pp. 135-138
[145.]
D. De Grandis.
Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review.
CNS Drugs, 21 (2007), pp. 39-43
[146.]
C.C. Verstappen, A.A. Geldof, T.J. Postma, J.J. Heimans.
In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.
J Neurooncol, 44 (1999), pp. 1-5
[147.]
J.E. Mollman, D.J. Glover, W.M. Hogan, R.E. Furman.
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.
Cancer, 61 (1988), pp. 2192-2195
[148.]
D.H. Moore, J. Donnelly, W.P. McGuire, L. Almadrones, D.F. Cella, T.J. Herzog, Gynecologic Oncology Group, et al.
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
J Clin Oncol, 21 (2003), pp. 4207-4213
[149.]
R. Leone, M.E. Fracasso, E. Soresi, G. Cimino, M. Tedeschi, D. Castoldi, et al.
Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Cancer Chemother Pharmacol, 29 (1992), pp. 385-390
[150.]
P.C. Lin, M.Y. Lee, W.S. Wang, C.C. Yen, T.C. Chao, L.T. Hsiao, et al.
N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data.
Support Care Cancer, 14 (2006), pp. 484-487
[151.]
E.M. Park, J.H. Choi, J.S. Park, M.Y. Han, Y.M. Park.
Measurement of glutathione oxidation and 8-hydroxy-2’-deoxyguanosine accumulation in the gerbil hippocampus following global ischemia.
Brain Res Brain Res Protoc, 6 (2000), pp. 25-32
[152.]
J. Albers, V. Chaudhry, G. Cavaletti, R. Donehower.
Interventions for preventing neuropathy caused by cisplatin and related compounds.
Cochrane Database Syst Rev, (2007), pp. CD005228
[153.]
L. Bove, M. Picardo, V. Maresca, B. Jandolo, A. Pace.
A pilot study on the relation between cisplatin neuropathy and vitamin E.
J Exp Clin Cancer Res, 20 (2001), pp. 277-280
[154.]
A. Pace, A. Savarese, M. Picardo, V. Maresca, U. Pacetti, G. Del Monte, et al.
Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.
J Clin Oncol, 21 (2003), pp. 927-931
[155.]
A.A. Argyriou, E. Chroni, A. Koutras, J. Ellul, S. Papapetropoulos, G. Katsoulas, et al.
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
Neurology, 64 (2005), pp. 26-31
[156.]
A.A. Argyriou, E. Chroni, A. Koutras, G. Iconomou, S. Papapetropoulos, P. Polychronopoulos, et al.
A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results.
Support Care Cancer, 14 (2006), pp. 1134-1140
[157.]
A.A. Argyriou, E. Chroni, A. Koutras, G. Iconomou, S. Papapetropoulos, P. Polychronopoulos, et al.
Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation.
J Pain Symptom Manage, 32 (2006), pp. 237-244
[158.]
L. Kottschade, C. Loprinzi, R. Rao.
Vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: rationale for an ongoing clinical trial.
Support Cancer Ther, 4 (2007), pp. 251-253
[159.]
R.H. Wilson, T. Lehky, R.R. Thomas, M.G. Quinn, M.K. Floeter, J.L. Grem.
Acute oxaliplatin-induced peripheral nerve hyperexcitability.
J Clin Oncol, 20 (2002), pp. 1767-1774
[160.]
S. Von Delius, F. Eckel, S. Wagenpfeil, M. Mayr, K. Stock, F. Kullmann, et al.
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study.
Invest New Drugs, 25 (2007), pp. 173-180
[161.]
A.A. Argyriou, E. Chroni, P. Polychronopoulos, G. Iconomou, A. Koutras, T. Makatsoris, et al.
Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
Neurology, 67 (2006), pp. 2253-2255
[162.]
R.G. Van der Hoop, C.J. Vecht, M.E. Van der Burg, A. Elderson, W. Boogerd, J.J. Heimans, et al.
Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.
N Engl J Med, 322 (1990), pp. 89-94
[163.]
J.A. Roberts, E.L. Jenison, K. Kim, D. Clarke-Pearson, A. Langleben.
A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
Gynecol Oncol, 67 (1997), pp. 172-177
[164.]
S. Koeppen, C.C. Verstappen, R. Körte, M.E. Scheulen, D. Strumberg, T.J. Postma, et al.
Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.
J Cancer Res Clin Oncol, 130 (2004), pp. 153-160
[165.]
J.E. Hammack, J.C. Michalak, C.L. Loprinzi, J.A. Sloan, P.J. Novotny, G.S. Soori, et al.
Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy.
Pain, 98 (2002), pp. 195-203
[166.]
A.L. Kautio, M. Haanpää, T. Saarto, E. Kalso.
Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms.
J Pain Symptom Manage, 35 (2008), pp. 31-39
[167.]
R.D. Rao, J.C. Michalak, J.A. Sloan, C.L. Loprinzi, G.S. Soori, D.A. Nikcevich, North Central Cancer Treatment Group, et al.
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Cancer, 110 (2007), pp. 2110-2118
[168.]
R.D. Rao, P.J. Flynn, J.A. Sloan, G.Y. Wong, P. Novotny, D.B. Johnson, et al.
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3.
Cancer, 112 (2008), pp. 2802-2808
[169.]
J.P. Durand, J. Alexandre, L. Guillevin, F. Goldwasser.
Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.
Anticancer Drugs, 16 (2005), pp. 587-591
[170.]
P. Vondracek, H. Oslejskova, T. Kepak, P. Mazanek, J. Sterba, M. Rysava, et al.
Efficacy of pregabalin in neuropathic pain in paediatric oncological patients.
Eur J Paediatr Neurol, 13 (2009), pp. 332-336
[171.]
L.A. Colvin, P.R. Johnson, R. Mitchell, S.M. Fleetwood-Walker, M. Fallon.
From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
J Clin Oncol, 26 (2008), pp. 4519-4520
Copyright © 2010. Sociedad Española de Neurología
